Diskusjon Triggere Porteføljer Aksjonærlister

Photocure fundamentale forhold (PHO)

Photocure ASA: Exercise of employee share options and share capital increase

Photocure ASA: Acquisition of own shares under the share buy-back program for incentive scheme

Photocure ASA: Exercise of employee share options

3 Likes

Positive Data from the Danish National Patient Registry presented at the 2022 Nordic Urologisk Forening (NUF) Congress in Helsinki

9 Likes

Photocure ASA: Share capital increase registered

Urologic Oncology: Seminars and Original Investigations
Available online 22 June 2022
In Press, Corrected ProofWhat are Corrected Proof articles?
Clinical-Bladder cancer
Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study

Highlights

Repeat instillation of
hexaminolevulinate (HAL) is safe.

Systemic adverse reactions from HAL are rare.HAL is safe following recent intravesical Bacillus Calmette-Guérin.

Abstract

Purpose

The therapeutic benefit of intravesical instillation of hexaminolevulinate (HAL) at the time of transurethral resection of bladder tumor (TURBT) has been demonstrated in multiple studies. The purpose of this study was to prospectively assess the safety of repeated administration of HAL from a phase III pre-trial planned analysis.

Materials and methods

All patients evaluated in the study received at least 1 dose of HAL at the time of office cystoscopy, and a subset of these patients (n = 103, 33.2%) received a second dose a few weeks later at the time of TURBT. Adverse events (AEs) were recorded, and the safety of repeat use of HAL was determined by comparing the proportion of patients with AEs considered causally related to HAL in the surveillance examination compared to the OR examination. Association between categorical variables was tested using Fisher’s Exact Test, and a P < 0.05 was considered statistically significant.

Results

HAL-related AEs were experienced by 6 patients (2.2%) during surveillance cystoscopy and 3 patients (3.4%) following TURBT (P = 0.76); 181 patients (59.5%) had prior exposure to HAL before enrolling in the study with no difference in the number of AEs when comparing prior exposure to HAL to no prior exposure (P = 0.76). Of the patients who previously received intravesical therapy, 8 (2.9%) had at least 1 AE during surveillance compared to 3 (9.7%) who had no prior intravesical therapy (P = 0.09).

Conclusions

Repeat use of HAL is safe even when administered within a few weeks of receiving a dose of intravesical therapy.

https://www.roche.com/investors/updates/inv-update-2022-06-16

Merlin skriver på HO:

"Roche launches human papillomavirus (HPV) self-sampling solution, expanding cervical cancer screening options

En slik screening kan bety voldsom etterspørsel etter Cevira, siden screeningen vil avsløre skjulte tilfeller. Dermed er Cevira mer aktuelt enn noensinne."

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre :slight_smile:

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

  1. @Rodjer (101 likes)
  1. @Savepig (63 likes)
  1. @roblar (42 likes)

Resten av topp 10:

  1. @gabster (41 likes)

  2. @kreinh (38 likes)

  3. @TyrionIV (12 likes)

  4. @Quadruple (12 likes)

  5. @myk (12 likes)

  6. @rosk82 (9 likes)

  7. @theroger (8 likes)

Gratulerer!

Photocure Collaborations at EAU Support the Latest Advancements in Bladder Cancer Technology

6 Likes

Photocure ASA – Share option grant

Photocure Provides Update on Anticipated Commercial Availability of Karl Storz’s New Blue Light System in the United States

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre :slight_smile:

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

  1. @Savepig (74 likes)
  1. @Rodjer (71 likes)
  1. @roblar (44 likes)

Resten av topp 10:

  1. @gabster (30 likes)

  2. @kreinh (29 likes)

  3. @myk (23 likes)

  4. @Hayen (20 likes)

  5. @Quadruple (10 likes)

  6. @rosk82 (9 likes)

  7. @Snoeffelen (8 likes)

Gratulerer!

Norne tar ned kursmålet i forkant av kvartalspresentasjonen, men venter vekst:

"Post-pandemic comeback should be seen

We keep our Buy recommendation on PHO share at a lower TP of NOK 120/sh (140) ahead of 2Q report next week, where we expect solid growth to be seen in the figures.

Solid growth and near-zero EBITDA expected for 2Q

Photocure will release its 2Q22 report on August 10th. Our estimates stand at NOK 97m for revenues, which is 19% growth QoQ and 7% YoY. We expect that a better access to hospitals should lead to better sales figures for both Europe and the US after a rather sluggish start of the year. Currency should also play a big role due to the massive strengthening of the USD lately. Notably, this affects not only on the top line but costs as well. Therefore, we still see EBITDA marginally in the negative territory at NOK -2.5m for the closed quarter, as the company ramps up its sales efforts especially in Europe."

Photocure ASA: Invitation to presentation of second quarter and first half year 2022 financial results

Photocure Partner Asieris Announces Completion of Patient Enrollment in Cevira Phase III Clinical Trial

23 Likes

Finfint å ha dette på plass til kvartalsrapport!

3 Likes

Photocure ASA: Results for the second quarter of 2022

3 Likes

Resultatreduksjon for Photocure: Ned 4,4 millioner kroner

Veldig godt intervju med DS

Photocure appoints Anders Neijber, MD, PhD as Chief Medical Officer, Global Medical Affairs and Clinical Development